Ibrutinib for the treatment of Waldenström macroglobulinemia.
Rochester, United States. In Expert Rev Hematol, 02 Aug 2015
Ibrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, is the first drug approved specifically for WM by the FDA after a clinical trial showed impressive response in previously treated WM.
[Ibrutinib: A new drug of B-cell malignancies].
Paris, France. In Bull Cancer, 30 Jun 2015
Ibrutinib (Imbruvica(®)) is a first-in-class, orally administered once-daily, that inhibits B-cell antigen receptor signaling downstream of Bruton's tyrosine kinase (BTK).
B-cell receptor signaling in diffuse large B-cell lymphoma.
Bethesda, United States. In Semin Hematol, Apr 2015
Pharmacological inhibition with ibrutinib of Bruton's tyrosine kinase, a kinase that is required for BCR signaling to engage NF-κB, is selectively toxic for ABC DLBCL tumors; a finding that has now been translated to the clinic.
Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Ann Arbor, United States. In J Oncol Pharm Pract, Mar 2015
New therapies currently in the drug development pipeline for relapsed and refractory disease include additional proteasome inhibitors (oprozomib, marizomib, ixazomib), histone deacetylase inhibitors (panobinostat, ricolinostat, quisinostat), monoclonal antibodies (daratumumab, elotuzumab, SAR650984), Bruton's tyrosine kinase inhibitors (ibrutinib), a selective inhibitor of nuclear export, and others.